These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27402144)

  • 21. Timing of treatment of smoldering myeloma: early treatment.
    Mateos MV; González-Calle V
    Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
    Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
    Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical Controversies in the Management of Smoldering Multiple Myeloma.
    Lomas OC; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-6. PubMed ID: 32223666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not Available].
    Z Gastroenterol; 2021 May; 59(5):493-494. PubMed ID: 34224130
    [No Abstract]   [Full Text] [Related]  

  • 25. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
    Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 27. [CME: Multiple Myeloma - a Review].
    Bräutigam M; Biskup E
    Praxis (Bern 1994); 2018 Jul; 107(14):749-754. PubMed ID: 29969971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of treatment of smoldering myeloma: delay until progression.
    Kumar SK
    Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
    Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
    Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
    [No Abstract]   [Full Text] [Related]  

  • 32. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, incidence and survival of smoldering multiple myeloma in the United States.
    Ravindran A; Bartley AC; Holton SJ; Gonsalves WI; Kapoor P; Siddiqui MA; Hashmi SK; Marshall AL; Ashrani AA; Dispenzieri A; Kyle RA; Rajkumar SV; Go RS
    Blood Cancer J; 2016 Oct; 6(10):e486. PubMed ID: 27768092
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of high-risk smoldering myeloma.
    Korde N
    Semin Oncol; 2016 Dec; 43(6):695-696. PubMed ID: 28061988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
    Khan R; Dhodapkar M; Rosenthal A; Heuck C; Papanikolaou X; Qu P; van Rhee F; Zangari M; Jethava Y; Epstein J; Yaccoby S; Hoering A; Crowley J; Petty N; Bailey C; Morgan G; Barlogie B
    Haematologica; 2015 Sep; 100(9):1214-21. PubMed ID: 26022710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Spectrum of monoclonal gammopathies].
    Matuszkiewicz-Rowińska J; Wieliczko M
    Wiad Lek; 2017; 70(6 pt 2):1170-1174. PubMed ID: 29533907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of asymptomatic myeloma patients.
    Mateos MV
    Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How We Approach Smoldering Multiple Myeloma.
    Raje N; Yee AJ
    J Clin Oncol; 2020 Apr; 38(11):1119-1125. PubMed ID: 32004107
    [No Abstract]   [Full Text] [Related]  

  • 40. Smoldering multiple myeloma: to treat or not to treat.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S
    Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.